title: BILATERAL CENTRAL RETINAL VEIN OCCLUSIONS IN A YOUNG PATIENT WITH A HISTORY OF EOSINOPHILIC PNEUMONIA AND THALAMIC STROKE.
abstract: OBJECTIVE
  To describe a case of a central retinal vein occlusion in a young patient with a history of eosinophilic pneumonia.
  
  
  METHODS
  A retrospective case report of a 45-year-old woman with acute painless vision loss for 9 days after multiple episodes of eosinophilic pneumonia and thalamic stroke. Fluorescein angiography, spectral domain optical coherence tomography, and clinical examination were performed. She was then treated with intravitreal bevacizumab and pan-retinal photocoagulations.
  
  
  RESULTS
  Retinal examination revealed tortuosity and dilatation of all branches of the central retinal vein and flame-shaped hemorrhages in all four quadrants of the right eye associated with cystoid macular edema, optic disc edema, and cotton wool spots. The left eye had mild venous dilatation and tortuosity with a few dot retinal hemorrhages in the far temporal periphery. The cystoid macular edema resolved after one intravitreal injection of bevacizumab and remained resolved at the most recent follow-up. Fluorescein angiography at the most recent follow-up revealed vasculitis in the far periphery of the nontreated eye.
  
  
  CONCLUSIONS
  Central retinal vein occlusion in young patients is a rare condition often presenting as a manifestation of an underlying inflammatory or hematological disorder. Combined anti-vascular endothelial growth factor treatment and pan-retinal photocoagulation may have resolved the associated cystoid macular edema in this case, although continued observation is necessary.
authors.affiliation: Department of Ophthalmology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.|University of Michigan Medical School, Ann Arbor, Michigan.
authors.forename: Gina
authors.initials: G
authors.lastname: Yu
authors.affiliation: Department of Ophthalmology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.|Department of Ophthalmology, First Hospital of China Medical University, Shenyang, People's Republic of China.
authors.forename: Peng
authors.initials: P
authors.lastname: Sun
authors.affiliation: Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts.
authors.forename: Tavé
authors.initials: T
authors.lastname: van Zyl
authors.affiliation: Department of Ophthalmology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
authors.forename: Rachel
authors.initials: R
authors.lastname: Tandias
authors.affiliation: Department of Ophthalmology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
authors.forename: Jorge G
authors.initials: JG
authors.lastname: Arroyo
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008028:Light Coagulation; D008875:Middle Aged; D011657:Pulmonary Eosinophilia / Q000150:complications*; D012170:Retinal Vein Occlusion / Q000209:etiology* / Q000628:therapy; D012189:Retrospective Studies; D020521:Stroke / Q000150:complications*; D013786:Thalamic Diseases / Q000150:complications*
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab